Cervical facet pain and regenerative approaches to the neck

Regenerative injection for cervical facet pain is an open question with real data on both sides. It is not a settled treatment, and it is not a dead end. As of 2026 there is one randomized controlled trial in this joint. In it, platelet-rich plasma and a corticosteroid gave similar pain relief over six months [3]. Several prospective and registry series also report real gains in pain and neck disability at three, twelve, and twenty-four months [4][6][7]. A 2025 systematic review grades the evidence for platelet-rich plasma in facet joints as moderate at best. It calls it limited overall, with low certainty [8].

That is the honest summary. What it hides is who those studies enrolled. Every one of them screened patients before treating them. Those screens cut out much of what walks into a chronic pain practice. Out went nerve root involvement, prior neck surgery, recent ablation, and unstable psychiatric conditions. In most of this work, so did anyone whose neck pain did not start with a whiplash injury.

One thing can be done well right now. That is the diagnostic work that decides whether your facet joints cause your pain at all. An injection aimed at the wrong structure fails, no matter what is in the syringe.

What is cervical facet pain, and how often are the facet joints the cause?

Cervical facet pain is neck pain from the zygapophysial joints. These are the small paired joints at the back of each spinal segment. They guide and limit motion. The pain usually comes with movement and with tenderness in one spot. It overlaps with disc pain, muscle pain, and pain referred from nearby structures.

The facet joints are a common source, but not the only one. One study looked at 68 patients in a row with neck pain lasting more than three months after a whiplash injury. Using placebo-controlled diagnostic blocks, it put the rate of cervical zygapophysial joint pain at 60% (95% confidence interval 46% to 73%) [1]. That figure fits one group: post-whiplash chronic neck pain sent to a specialist clinic. It is not the rate across all neck pain.

The same study is a warning the other way. It used a placebo shot of normal saline plus two different local anesthetics. Neither patients nor doctors knew which was which. The authors did this because they feared simpler blocks might overstate the condition [1]. Careful diagnosis narrows the field both ways.

Why the imaging report is not the answer

Wear at the cervical facet joints is common in people with no neck pain. One computed tomography study scanned 500 cervical facet joints in 50 adults aged 20 to 69. They were scanned for other reasons, such as thyroid disease or cancer screening. Anyone with a record or history of neck or back pain was excluded. Even so, 33% had facet arthritis of grade 1 to 3 (grade 1, 19%; grade 2, 11%; grade 3, 3%) [2]. Among those older than 40, arthritic change at C6–C7 showed up in 78% [2].

So a report of facet arthropathy describes anatomy. It does not find your pain source. Treating the picture instead of the patient is how injections land at the wrong level. The study’s authors name its own limit. It looked back at old records, and subjects were not asked about mild or unrecorded pain [2].

How the source of pain is narrowed down

Narrowing it down takes several steps. We take your history and test which movements cause pain. We check your imaging against your actual symptoms. Where it fits, we use diagnostic blocks of the medial branch nerves that supply the joint. Both the randomized trial and the largest prospective series required a positive block before anyone was injected [3][4]. That shows how central the step is.

That sequence is the same whether the final plan is regenerative, interventional, or conservative. It is also the step most often skipped.

What does the research show about regenerative injections for neck facet pain?

There are five relevant papers, and they do not all point the same way. Together they describe a treatment that looks safe in small groups. The gains are real in the people measured. But it has not been shown to beat what is already done.

The one randomized trial

A single-site randomized, double-blind trial ran in London, Ontario. It compared leukocyte-poor, low-concentrate platelet-rich plasma against a corticosteroid shot. Both went into the cervical facet joints under fluoroscopy (live X-ray). Results were taken at one, three, and six months [3]. Fifty-five people enrolled and 40 were analyzed. Of those, 21 got platelet-rich plasma [3][5]. Both treatments cut pain about the same over six months. Pain relief matched at one month, and disability gains matched at three and six months. The platelet-rich plasma group felt significantly less pain during the procedure. At one month they also gained more confidence in handling their pain [3].

Similar is not the same as useless. The comparison was an active drug already used for this problem, not a placebo. So the trial answers “is this better than a steroid injection” and does not answer “does this do anything at all.” A trial this size also cannot rule out a small difference it was not built to detect.

Who got in matters as much as the result. Participants had to be at least 18. They needed facet neck pain of at least 4 out of 10 after a whiplash injury. They needed at least 50% relief of their usual neck pain from two cervical medial branch blocks [3]. Several groups were kept out. These included suspected serious spinal disease and fracture or dislocation at the time of injury. Nerve root compromise was out. So was spinal surgery or radiofrequency neurotomy in the past 12 months. So was a corticosteroid cervical facet shot in the past six months. Any history of uncontrolled mental health conditions was out, along with other reasons not to inject the spine [3].

Read that list as a picture of who the result applies to. It fits people whose pain began with whiplash, who passed a block, and who never had surgery. It covers one site, six months of follow-up, and one type of platelet-rich plasma at one strength. Facet pain from wear, with no injury at the start, was not studied here.

The prospective series, and the patients in them

Three series report on regenerative injection in the neck, and each enrolled a different kind of patient.

A Calgary clinic series treated 44 people with chronic whiplash-associated disorder. They were 82% female, with a mean age of 45.2 years and a median symptom time of 24 months. Each got one leukocyte-rich platelet-rich plasma injection into the cervical facet joints. Fluoroscopy or ultrasound guided the needle [4]. At three months, average pain fell from 5.8 to 3.7 on a 0–10 scale. Neck Disability Index scores fell from 45.2% to 30.7%. Both had p<0.001. For pain, 70% passed the smallest change that patients notice. For disability, 80% did. And 41% reported more than 50% pain relief [4]. No adverse events were reported [4]. To enter, patients needed whiplash-associated disorder grade II lasting more than three months. They had to fail at least six weeks of conservative therapy such as physiotherapy, chiropractic or massage. They also needed a positive diagnostic medial branch block [4].

An earlier Canadian case review treated 18 cervical zygapophysial joint sides. These patients had chronic whiplash neck pain that had already failed other conservative and interventional care. Each got 0.5 to 1 mL of 20% dextrose into the joint. Fluoroscopy and contrast dye confirmed the needle spot [6]. Fifteen patients finished treatment. Mean Neck Disability Index was 24.71 before treatment. It fell to 14.21 at two months, 13.45 at six months, and 10.94 at twelve months. That is an average drop of 13.77 from baseline to twelve months (p<0.0001) [6]. In 14 patients, symptoms followed a motor vehicle accident. Of those, 13 were in litigation, a group most trials screen out. The authors said litigation did not block recovery [6].

The third paper gave this field its functional spinal unit framing. It is a registry case series. It treats the disc, facet joints, and supporting ligaments of a neck segment as one mechanical unit, not as separate targets [7]. Patients were treated between August 2014 and March 2017 with platelet-rich plasma, platelet lysate, or dextrose prolotherapy. Only 14 had full two-year data [7]. Those 14 had a mean age of 59.8 years and were 64% female. At 24 months, pain scores fell by a mean of 2.8 points (p=0.002). Functional Rating Index scores fell by 27.3 points (p=0.004). On each, 79% passed the smallest change patients notice [7]. Two of the 14 reported adverse events. One had a skin rash with more pain after the procedure. One had itching at the injection site. Both cleared on their own [7]. The paper lists no formal exclusion criteria. Its authors say larger randomized controlled trials are needed to confirm the findings [7].

Why the preparation is not a detail

A 2025 pooled analysis compared the two preparations head to head. It set 36 people who got leukocyte-rich platelet-rich plasma in the Calgary series against 21 who got leukocyte-poor platelet-rich plasma in the randomized trial [5]. At six months the leukocyte-rich group did better on pain (β = −1.68, p<0.01). It also did better on the Neck Disability Index (β = −3.66, p=0.02). A pain drop of at least two points came in 63.9% versus 28.6% (p=0.02). A disability gain of at least 10% came in 90.3% versus 61.9% (p=0.03) [5]. At three months there were no significant differences [5].

Take that with the caution its own authors give. Pooling a case series with a randomized trial mixes different designs. Patient selection, blinding, preparation methods, and injection technique all differ. Platelet counts were also not routinely measured for the leukocyte-poor product [5]. It is a signal that preparation matters. It is not proof of which one to use.

This is a big reason the field is unsettled. Studies differ in platelet strength, white cell content, and injected volume. They differ in how many joints get treated and how far apart the shots are. Samples are small. Studies with the same three-letter label often test different things. Our orthobiologics overview sets out which preparations we use and for which regions.

How the whole body of evidence is graded

A 2025 systematic review looked at regenerative medicine for spine pain coming from the facet joints. It found four randomized controlled trials and six observational studies. Most were in the lower back [8]. It graded the evidence for platelet-rich plasma shots in facet joints as Level II, or moderate. Overall it rated it Level IV, or limited, with low certainty. It gave platelet-rich plasma a moderate recommendation and mesenchymal stem cells a weak one [8].

Moderate-to-limited with low certainty is a fair summary of where this stands. It is not nothing. It is not enough to promise you an outcome.

Who these studies left out, and why that matters if your case is complicated

The gap between a trial result and your case is not a matter of opinion. It is written into the methods sections, and they are worth reading.

The exclusions that are written down

Across the neck studies above, these were the stated exclusions [3][4]. Nerve root compromise was out. So was fracture or dislocation at the time of injury, and whiplash-associated disorder grades III and IV. So was known or suspected serious spinal disease, such as metastatic disease of the spine. Previous cervical spine surgery was out. So was spinal surgery or radiofrequency neurotomy within 12 months. So was a cervical facet corticosteroid shot in the past three to six months. Post-concussion syndrome was out. So was a history of bipolar disorder, psychosis or schizophrenia, or any uncontrolled mental health condition. Patients also had to stop anti-inflammatory drugs for three days before and ten days after the shot. And they had to read and complete the questionnaires in English.

Each of those makes sense as trial design. Together they describe a fairly simple patient. Maybe you have had a fusion. Maybe you have arm nerve pain on top of neck pain. Maybe your last steroid shot was two months ago. Maybe you take an anti-inflammatory you cannot stop for two weeks. Maybe you have a psychiatric diagnosis that is managed but not gone. Then you would not have been enrolled in these studies. Their numbers were never a forecast for you.

That cuts both ways, and we will say it plainly. Being screened out is not evidence a treatment would work better for you. It is evidence that nobody measured.

The exclusion nobody wrote down

None of the neck studies cited here reports the metabolic status of its patients. Body mass index, hemoglobin A1c, diabetes, insulin resistance, and inflammatory or autoimmune disease are missing. They do not appear in the baseline data of the randomized trial, the prospective series, the case review, or the registry series [3][4][6][7]. Only the observational radiofrequency study below names unrecorded health conditions as a possible source of bias in its own data [9].

That is a gap you can check in the published record. It is not our reading of it. Regen.MD checks metabolic markers before treating, because the metabolic and inflammatory terrain under joint breakdown is central to how this practice frames a degenerative problem. But the neck facet studies cannot tell you how these shots work in someone with poorly controlled diabetes or heavy insulin resistance. They cannot say better or worse, because no one recorded it.

The selection nobody controls

Two of the series name a selection effect that has nothing to do with medicine. In the Calgary series and the two-year registry series, insurance did not cover these treatments. Many patients paid for them out of their own pocket. Both papers warn that wealth is linked to better health. So their results may not apply to the wider population [4][7]. The registry paper adds one more point. Paying out of pocket could, in theory, make a patient more eager to see improvement [7].

Coverage is a payer decision, not a clinical finding. Insurers decide what they will pay for on their own terms, and patients here sign an Advance Beneficiary Notice for services that are not covered. A service that is not covered is not useless because of that. This page does not use a payer’s stance as an argument either way. It does skew who ends up in the published studies, and that is worth knowing when you read them.

What single-modality trials cannot test

All of these studies tested an injection more or less by itself. That is sound study design. It is not how care is delivered.

The studies keep running into this. In the Calgary series, patients were urged to do physiotherapy after the shot. No one tracked who went. The authors note any gain likely reflects platelet-rich plasma and physiotherapy together, not either alone [4]. In the earlier dextrose review, patients who went to physiotherapy did better than those who did not. The authors said physiotherapy at the same time helped ease neck stiffness after the procedure [6]. The registry series treated disc, facet joints and ligaments as one unit. So it cannot credit its result to the facet shot alone [7].

None of that proves combined care works better. It does prove the published evidence is not a clean test of what most patients ask. That question is this: does a planned program with an injection beat the same program without it? That study has not been done in the neck.

How long anyone was followed

Follow-up runs to three months in the Calgary series. It runs six months in the randomized trial and the pooled analysis. It runs twelve months in the dextrose review and twenty-four months in the registry series [3][4][5][6][7]. Nothing here speaks to what happens after two years. None of these studies can support a claim that the effect lasts, and we do not make it.

Is radiofrequency ablation a regenerative treatment for neck facet pain?

Radiofrequency neurolysis is not a regenerative treatment. It uses heat to shut down the medial branch nerves that carry pain from the facet joint. It does not repair a joint. It cuts the nerve supply, and the nerve grows back over time. Regen.MD offers it. Its evidence base in the neck is larger than the regenerative evidence. So it belongs on this page, even though it answers a different question.

The largest recent dataset is the neck group of the RAPID study. It is an international, multicenter, prospective observational study. Boston Scientific Corporation sponsored it, and it used that maker’s commercially available radiofrequency system [9]. We disclose the funding because it should weigh on how you read the numbers. Several authors report consulting or advisory ties to the sponsor, and three are its employees [9].

Fifty-six patients with chronic cervical facet pain enrolled. They were 60.7% female, with a mean age of 59.5 years. Mean pain duration was 9.5 years, and 75% had at least two years of pain. Mean baseline pain was 6.0 ± 1.97. Mean Oswestry Disability Index was 32.7 ± 15.6 [9]. Mean pain fell to 3.3 ± 2.8 at six months (n=49). It was 3.3 ± 2.2 at twelve months (n=40). Both had p<0.0001. Oswestry scores improved by 7.9 and 9.7 points [9]. At least 50% pain relief came in 81% at one month and 80% at twelve months [9]. No serious adverse events from the device or procedure were reported in this group [9].

The design cuts both ways, and this part is worth understanding. RAPID kept out only two groups. One was people whose memory or thinking was too impaired to rate their own pain. The other was anyone with a reason not to use the device listed in its instructions [9]. Nobody was screened out for other illness, prior surgery, length of symptoms, or general complexity. A mean of nearly a decade of pain reflects that. Real-world reach is exactly what this design buys.

What it gives up is control. There was no comparison group. So gains cannot be split from the natural course of the condition or from the effect of being enrolled and followed closely. The authors name unknown confounders and unrecorded health conditions as possible sources of bias. They note the number of diagnostic blocks was not the same across sites. Only 17 of the first 56 patients remained at 24 months. More than half of those had at least one repeat ablation [9]. Read the two-year figures with that in mind.

How is cervical facet joint pain treated, step by step?

Conservative care comes first, and for many people it is where the answer is. That means loading and movement work. It means addressing sleep, workstation, and posture. Give those steps a real trial with a set review date, not an open-ended one. Both neck series that reported on it found conservative care and injection tangled together, not opposed [4][6].

Suppose a set trial of conservative care has not met your goals. The next step is diagnostic, not treatment. It confirms whether the facet joints are really causing your pain. In the published studies that meant medial branch blocks [3][4]. Only then is there a real conversation about which injection, or whether an injection is the right move at all.

Suppose conservative care is used up and your goals are still not met. Then that conversation includes interventional options and, where indicated, surgery. Dr. Gurpreet Singh Padda, MD, MBA, MHP is a surgeon. Surgery is available here when it is warranted. It comes as a later step in the sequence, never as the first one.

“My ethos is to treat all of my patients as I would my own family, with the goal of giving them back their quality of life.” — Dr. Gurpreet Singh Padda, MD, MBA, MHP

How risk and benefit are discussed here

Plainly, and with the numbers that exist. Adverse events in the neck regenerative studies have been minor and short-lived. There were none among the 44 people in the Calgary series [4]. There were two of 14 in the registry series [7]. Rates were similar for platelet-rich plasma and corticosteroid in the randomized trial, and the platelet-rich plasma group felt less pain during the procedure [3]. The pooled analysis recorded 11 adverse events in the leukocyte-poor group: pain, spasms and headache. It recorded none in the leukocyte-rich group [5].

Those are small samples. Small samples catch common problems and miss rare ones. We state that limit instead of glossing over it. What we can tell you is what has been reported, in whom, and over what period. That is the same standard we use for the benefit figures above.

What we will not tell you

We will not tell you an injection rebuilds a cervical facet joint. We will not borrow a number from the knee and apply it to your neck, because results do not carry across joints by analogy. Knee joints are large, easy to reach, and far more studied. We will not present a six-month comparison as proof the effect lasts. We will not describe a group nobody studied as a group we know how to treat.

Where the evidence is missing, this page says so. Where it is truly unsettled, it says why.

Where to find us

Regen.MD is at 4477 Woodson Rd, Suite 103, St. Louis, MO 63134, next to St. Louis Lambert International Airport. Directions and parking are on the locations page, and you can reach the office at (314) 295-3000 or text (314) 886-5902.

When neck pain outlasts the tissue injury, the second half of the assessment is laid out in when the tissue has healed and the pain has not.

Frequently asked questions

Sources

1. Lord SM, Barnsley L, Wallis BJ, Bogduk N. Chronic cervical zygapophysial joint pain after whiplash. A placebo-controlled prevalence study. Spine (Phila Pa 1976). 1996;21(15):1737-1744. https://doi.org/10.1097/00007632-199608010-00005 (referenced for: 60% prevalence, 95% CI 46–73%, of cervical zygapophysial joint pain among 68 consecutive patients with chronic neck pain after whiplash, established with placebo-controlled diagnostic blocks).
2. Kim JH, Sharan A, Cho W, Emam M, Hagen M, Kim SY. The Prevalence of Asymptomatic Cervical and Lumbar Facet Arthropathy: A Computed Tomography Study. Asian Spine Journal. 2019;13(3):417-422. https://doi.org/10.31616/asj.2018.0235 (referenced for: 33% prevalence of grade 1–3 cervical facet arthritis across 500 facet joints in 50 asymptomatic adults, the grade breakdown, the 78% figure at C6–C7 in subjects older than 40, and the study’s retrospective limitation).
3. Allison DJ, Ebrahimzadeh S, Muise S, Joseph S, Roa Agudelo A, Lawson A, Billias N, Tran J, Smith A, Loh E. Intra-articular corticosteroid injections versus platelet-rich plasma as a treatment for cervical facetogenic pain: a randomized clinical trial. Regional Anesthesia and Pain Medicine. 2026;51(1):33-40. https://doi.org/10.1136/rapm-2024-105889 Trial registration ClinicalTrials.gov NCT04392999, https://clinicaltrials.gov/study/NCT04392999 (referenced for: the randomized double-blind design, 55 enrolled and 40 analyzed, comparable six-month outcomes between leukocyte-poor platelet-rich plasma and corticosteroid, lower procedural pain and greater one-month pain self-efficacy in the platelet-rich plasma group, and the registered inclusion and exclusion criteria).
4. Smith A, Andruski B, Deng G, Burnham R. Cervical facet joint platelet-rich plasma in people with chronic whiplash-associated disorders: A prospective case series of short-term outcomes. Interventional Pain Medicine. 2022;1(2):100078. https://doi.org/10.1016/j.inpm.2022.100078 (referenced for: n=44, demographics and median 24-month symptom duration, inclusion and exclusion criteria, three-month pain and Neck Disability Index results with p-values and responder percentages, absence of reported adverse events, the physiotherapy confound, and the out-of-pocket generalizability caution).
5. Allison DJ, Loh E, Burnham R, Burnham T, Smith A. Leukocyte poor platelet rich plasma vs leukocyte rich platelet rich plasma as a treatment for cervical facetogenic pain: A pooled analysis. Interventional Pain Medicine. 2025;4(1):100566. https://doi.org/10.1016/j.inpm.2025.100566 (referenced for: the 36 versus 21 pooled comparison, six-month pain and disability coefficients and responder percentages, the 11 adverse events in the leukocyte-poor group, and the authors’ limitations regarding pooling designs and unquantified platelet counts).
6. Hooper RA, Frizzell JB, Faris P. Case series on chronic whiplash related neck pain treated with intraarticular zygapophysial joint regeneration injection therapy. Pain Physician. 2007;10(2):313-318. https://doi.org/10.36076/ppj.2007/10/313 (referenced for: 18 treated sides in patients who had failed other conservative and interventional procedures, the 20% dextrose intra-articular technique, Neck Disability Index values at 2, 6 and 12 months with p<0.0001, the litigation finding, and the physiotherapy association).
7. Williams C, Jerome M, Fausel C, Dodson E, Stemper I, Centeno C. Regenerative Injection Treatments Utilizing Platelet Products and Prolotherapy for Cervical Spine Pain: A Functional Spinal Unit Approach. Cureus. 2021;13(10):e18608. https://doi.org/10.7759/cureus.18608 (referenced for: the functional spinal unit framework, n=14 with complete 24-month data, the treatment window and injectates, 24-month numeric pain score and Functional Rating Index changes with p-values and minimal clinically important difference percentages, the two adverse events, the absence of stated exclusion criteria, the out-of-pocket generalizability caution, and the authors’ call for larger randomized controlled trials).
8. Manchikanti L, Abd-Elsayed A, Kaye AD, Sanapati MR, Pampati V, Shekoohi S, Hirsch JA. A Systematic Review of Regenerative Medicine Therapies for Axial Spine Pain of Facet Joint Origin. Current Pain and Headache Reports. 2025;29(1):61. https://doi.org/10.1007/s11916-025-01376-1 (referenced for: four randomized controlled trials and six observational studies identified, the predominance of lumbar facet studies, the Level II moderate and Level IV limited grading with low certainty, and the moderate recommendation for platelet-rich plasma versus weak for mesenchymal stem cells).
9. Provenzano DA, Holt B, Danko M, Atallah J, Iqbal M, Shah B, Singh A, Sachdeva H, Ver Donck E, Liebrand B, Shaw E, Haas S, Sekhar R, Pan A, Halperin DS, Goldberg E. Assessment of real-world, prospective outcomes in patients treated with cervical radiofrequency ablation for chronic pain (RAPID). Interventional Pain Medicine. 2025;4(3):100623. https://doi.org/10.1016/j.inpm.2025.100623 Trial registration ClinicalTrials.gov NCT04673032, https://clinicaltrials.gov/study/NCT04673032 Funding disclosure: this study was sponsored by Boston Scientific Corporation, the manufacturer of the radiofrequency system studied; several authors report consulting or advisory relationships with the sponsor and three are employed by it. (Referenced for: the cervical cohort of 56 patients, demographics and 9.5-year mean pain duration, baseline and follow-up pain and Oswestry Disability Index values with p-values, responder rates, absence of serious device- or procedure-related adverse events, the minimal exclusion criteria, and the limitations regarding confounders, non-standardized diagnostic blocks and 24-month retention. This is radiofrequency ablation, not a regenerative treatment.)